Ads
related to: octapharma plasma customer service numberinfo.biolifeplasma.com has been visited by 10K+ users in the past month
- 2650 North High Street, Columbus, OH · Directions · (614) 267-4982
Search results
Results From The WOW.Com Content Network
Octapharma AG, founded in 1983 by Wolfgang Marguerre, is a family-owned pharmaceutical company based in Switzerland.It bills itself as "one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines."
CSL Plasma is a subsidiary of its sister company CSL Behring, itself a subsidiary of CSL Limited, a biotechnology company based in Melbourne, Australia. [2] [ P 2] It is headquartered in Boca Raton, Florida, [1] and operates a total of 320 collection centers in the United States, [P 3] and a further 19 more in other nations including China, Hungary, and Germany as of 2023.
Wolfgang Marguerre (born 1941) is a German billionaire businessman, the chairman and owner of the Octapharma Group. The pharmaceutical company produces medicine derived from human proteins to treat haematology, immunotherapy, intensive care, and emergency medicine.
Plasmapheresis (from the Greek πλάσμα, plasma, something molded, and ἀφαίρεσις aphairesis, taking away) is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation.
NYBC and its operating divisions also provide a wide array of transfusion-related medical services to over 500 hospitals nationally, including Comprehensive Cell Solutions, the National Center for Blood Group Genomics, the National Cord Blood Program, and the Lindsley F. Kimball Research Institute, which — among other milestones — developed ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
An International Quality Plasma Program (IQPP) facility is a lab that has agreed to the voluntary standards program of the PPTA. [3] The personally identifiable information (PII) that is collected is "individual's donor ID, first and last name, middle initial birthdate and gender. The donor's social security number or INDS number."
In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's." [13] In 2020 Grifols acquired the remaining stock of Alkahest “bringing its ownership of Alkahest to 100%”. [14]